22nd Century Group (NASDAQ: XXII) is a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies. The company is now selling the first and only 95% reduced nicotine content cigarette compliant with the renewed federal policy initiative to require all cigarettes sold in the U.S. be made minimally or non-addictive. “We are excited to pilot sales of the first and only cigarette designed specifically not to create and sustain addiction, but to instead reduce the hold of cigarette addiction on adult smokers,” said John Miller, president of 22nd Century’s tobacco programs. “The facts clearly demonstrate that the overwhelming majority of smokers want to quit, but few are able to do so, even after repeated attempts with current smoking cessation therapies or alternative nicotine products. VLN(R) from 22nd Century offers a new approach in this fight – a tobacco cigarette that actually helps adult smokers reduce their nicotine consumption and smoke less. We are hopeful that many will also go on to quit their habit of smoking highly addictive cigarettes entirely.”

To view the full press release, visit https://ibn.fm/Ms5DZ

About 22nd Century Group Inc.

22nd Century Group is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the company has developed proprietary reduced nicotine content (“RNC”) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s comprehensive plan to address the widespread death and disease caused by smoking. The company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant-breeding technologies, including genetic engineering, gene-editing and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. For more information about the company, visit www.XXIICentury.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.